Veradermics (MANE) Profit After Tax (2025 - 2026)
Veradermics' (MANE) quarterly Profit After Tax came in at -$584000.0 in Q1 2026, up 96.0% YoY from -$297966.7 in Q1 2025, and up 96.0% on a QoQ basis from -$14.6 million in Q1 2025.
Veradermics (MANE) Profit After Tax (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Profit After Tax data on file, last reported at -$584000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Veradermics | 4.70 Bn | 4.70 Bn | - | -23.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.87 Mn |
| Mar 31, 2026 | -584,000.00 |
| Mar 31, 2025 | -14.58 Mn |